Compare Intercontinental Exchange Inc. Common Stock (ICE) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intercontinental Exchange Inc. Common Stock vs Organon & Co. Common Stock — how do they compare? Intercontinental Exchange Inc. Common Stock trades at $156.7 (market cap $87.81B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Intercontinental Exchange Inc. Common Stock is far larger — about 24.3× Organon & Co. Common Stock's market cap, and Intercontinental Exchange Inc. Common Stock pays the higher dividend (1.33%). Which is the better fit depends on your goals.
| ICE | OGN | |
|---|---|---|
Market Cap | $87.81B | $3.62B |
Volume | 3,190,982 | 2,892,999 |
Sector | Financials | Health |
52-Week High | $175.10 | $13.81 |
52-Week Low | $122.91 | $5.70 |
Enterprise Value | $105.72B | $11.04B |
Dividend Yield | 1.33% | 0.58% |
Typical Hold Time | — | 0 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intercontinental Exchange (ICE) trades at $156.42, down 0.64% on the day, with strong technical momentum showing bullish moving averages and key support at $155. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $1.90 versus $1.84, maintaining a three-quarter beat streak. Revenue growth accelerated to $13.4 billion in 2026 with net profit margin expanding to 30.07%, supported by record trading volumes in key markets.
ICE presents a compelling investment case with 89% analyst buy ratings and a $183.89 consensus price target implying 17.6% upside. The exchange operator's diversified platform and recurring revenue model provide stability, though investors should monitor competitive pressures and market volatility impacts. Strong cash flow generation and institutional support reinforce the bullish outlook despite near-term technical overbought conditions.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Intercontinental Exchange Inc. Common Stock
Intercontinental Exchange provides technology and data services for financial institutions, corporations, and governments. Its businesses include exchanges and clearing, fixed-income data and analytics, and mortgage technology.
Read more on ICE →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
